Two Directors at BioArctic AB sold 2,400,000 shares at 300.000SEK. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
AUCTUS PUBLICATIONS ________________________________________ Pulsar Helium (PLSR LN/CN)C; Target price of £0.95 per share: Very high flow rate at Jetstream #1. £3.7 mm equity raise to drill up to 10 wells – Jetstream #1 recorded a peak flow rate exceeding 1.3 mmcf/d of raw gas during a compression-assisted test, with no formation water encountered. This represents a ~2.5-fold increase over the flow rate achieved without compression, and is approximately 60–65% higher than the rate recorded durin...
Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’ Den nye 5-årige strategi, Impact4, vil blive lanceret i dag på selskabets Capital Markets Day 2025. Strategien Impact4 sætter kunden i centrum og udstikker samtidig et ambitiøst mål for selskabet – at hjælpe 4 millioner mennesker på lang sigt. Med Impact4 fokuserer vi på fire strategiske prioriteter, der er afgørende for vores succes og værdiskabelse: ’Grow through innovative customer offerings’ ved at sætte standarden for sundhedspleje og ved at skabe et stærkt fokus på kunderne på tværs af alle vores forretningsområder.’Unl...
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4 The new 5-year strategy, Impact4, will be presented today at the company’s Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to help 4 million people in the long-term. With Impact4, we focus on four strategic priorities which are essential to our success and value creation: Grow through innovative customer offerings, by setting the standard of care and driving strong customer centricity across all our business areas.Unlock next level e...
Equinor ASA: Share buy-back – third tranche for 2025 Please see below information about transactions made under the third tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO). Date on which the buy-back tranche was announced: 23 July 2025. The duration of the buy-back tranche: 24 July to no later than 27 October 2025. Further information on the tranche can be found in the stock market announcement on its commencement dated 23 July 2025, available here: From 25 August to 29 August 2025, Equinor ASA has purchased a total of 1,360,961 ...
Equinor ASA: Tilbakekjøp av egne aksjer – tredje transje for 2025 Nedenfor følger informasjon om transaksjoner foretatt under tredje transje av Equinor ASAs (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO) tilbakekjøpsprogram for 2025. Dato for når tilbakekjøpstransjen ble annonsert: 23. juli 2025. Tilbakekjøpstransjens varighet: 24. juli til senest 27. oktober 2025. Ytterligere informasjon om transjen kan finnes i børsmelding om dens oppstart datert 23. juli 2025, tilgjengelig her: Fra 25. august til 29. august 2025, har Equinor ASA kjøpt tilbake totalt 1.360.961 egne aksjer til en gjenn...
Coloplast A/S - Announcement no. 07/2025 - Coloplast fremlægger nye finansielle forventninger frem mod 2030 I forbindelse med lanceringen af Coloplasts nye 5-årige strategi, Impact4, offentliggør virksomheden en ny finansiel ambition med en organisk omsætningsvækst på 7-8 % (5-årige CAGR) frem til regnskabsåret 2029/30, en vækst i absolut EBIT* på niveau med eller over omsætningsvæksten i perioden og et afkast af investeret kapital (ROIC) på mere end 20 % i regnskabsåret 2029/30. På sin Capital Markets Day den 2. september 2025 vil Coloplast præsentere en ny 5-årig strategi, Impact4. I fo...
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial ambition towards 2030 In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in line with or above revenue growth over the period and Return on Invested Capital (ROIC) of more than 20% in FY 2029/30. At its Capital Markets Day on 2 September 2025, Coloplast will present a new 5-year strategy, Impact4. In relation to the strategic update, Coloplast is providing a new long-te...
Equinor to participate in Ørsted Rights Issue Equinor (OSE, NYSE: EQNR) has assessed the proposal put forward by the Board of Directors of Ørsted A/S on 11 August 2025 for a Rights Issue with pre-emptive rights for existing shareholders (the “Rights Issue”). Following dialogue with Ørsted, Equinor has decided to support the proposal to strengthen Ørsted’s balance sheet in response to the current industry challenges. As a long-term industrial shareholder, Equinor intends to participate in the Rights Issue and maintain its 10% ownership share in Ørsted. Ahead of the next annual general meet...
Equinor vil delta i emisjonen i Ørsted Equinor (OSE, NYSE:EQNR) har vurdert forslaget styret i Ørsted fremmet 11. august 2025 om en emisjon med fortrinnsrett for eksisterende aksjonærer («Emisjonen»). Etter dialog med Ørsted, har Equinor besluttet å støtte forslaget, som vil styrke balansen til Ørsted som en respons på utfordringene industrien nå står overfor. Som en langsiktig og industriell eier, er Equinors intensjon å delta i Emisjonen og opprettholde en eierandel på 10 % i Ørsted. I forkant av Ørsteds neste ordinære generalforsamling vil Equinor fremme en kandidat til styret. Equino...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.